Childhood neoplasm
MONDO:0021079A benign or malignant neoplasm arising during childhood.
Also known as: childhood neoplasm, childhood neoplasm (disease), childhood tumor, childhood tumour, neoplasm (disease) of childhood, paediatric neoplasm, paediatric neoplasm (disease), paediatric tumour
1835 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
Custom-Made cancer vaccine tested in 25 patients
⭐️ VACCINE ⭐️ CompletedThis study tested whether a personalized vaccine could be safely made and given to 25 adults with advanced cancers that cannot be cured. The vaccine was custom-made for each person. The main goal was to check for side effects and see if the approach is feasible.
Phase: PHASE1 • Sponsor: Aaron Miller • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tests an experimental drug called XmAb24306, given alone or with another cancer drug (atezolizumab), in people with advanced solid tumors that cannot be cured. The main goal is to check the drug's safety and how the body processes it. About 195 participants will take p…
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Experimental cell therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tests an experimental cell therapy called IBR854 in people with advanced solid tumors that cannot be surgically removed or have spread. The main goals are to check the treatment's safety and find the right dose. Participants receive the cells by infusion tw…
Phase: PHASE1 • Sponsor: Imbioray (Hangzhou) Biomedicine Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New pill takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tests an experimental tablet called YZJ-5053 in people with advanced solid tumors who have no standard treatment options left. The main goals are to find a safe dose and check for side effects. Researchers will also look at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Shanghai Haiyan Pharmaceutical Technology Co., Ltd. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Promising combo tackles tough cancers in early trial
Disease control CompletedThis early-phase study tested the safety of combining two drugs—pembrolizumab (an immunotherapy) and AMG386 (which targets blood vessel growth)—in 62 people with advanced solid tumors like melanoma, ovarian, renal, or colorectal cancer. The main goals were to find the safest dose…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage trial tested a new drug called BGB-15025, alone or with another drug (tislelizumab), in 157 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the best dose. The study is now complete, …
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New cancer drug combo tested in early human trial
Disease control CompletedThis early-phase trial tested an experimental drug called IOS-1002, given alone or with the immunotherapy pembrolizumab, in 47 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Research…
Phase: PHASE1 • Sponsor: ImmunOs Therapeutics AG • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug duo shows promise for Hard-to-Treat cancers
Disease control CompletedThis phase 2 study tested a combination of two drugs—olaparib and pembrolizumab—in 333 adults with advanced solid tumors that have specific DNA repair problems (HRR mutations or HRD). The goal was to see if the combo could shrink tumors or slow their growth. Participants had alre…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Chemotherapy showdown: which combo works best for T-Cell cancers in kids?
Disease control CompletedThis large phase 3 trial studied nearly 1,900 children and young adults with newly diagnosed T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Researchers compared different chemotherapy combinations, including varying doses of methotrexate and adding the drug…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug IBI129 tested in humans for first time against Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called IBI129 in 36 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find a safe dose and check for side effects. Researchers also looked for any signs that the drug mig…
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New cancer drug CFI-402257 enters first human trial
Disease control CompletedThis Phase 1 trial tested an investigational oral drug called CFI-402257 in 52 people with advanced solid tumors, including breast cancer, that had stopped responding to standard treatments. The main goal was to find a safe dose and check how the drug moves through the body. It w…
Phase: PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New immunotherapy cocktail aims to simplify cancer treatment
Disease control CompletedThis study tested a fixed-dose combination of two immunotherapy drugs, tiragolumab and atezolizumab, given together as a single infusion every three weeks. The trial enrolled 64 people with advanced solid tumors that express a protein called PD-L1. The main goal was to check the …
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control CompletedThis early-phase trial tested an experimental drug called KVA12123, given alone or with the immunotherapy Keytruda, in 40 adults with advanced solid tumors (like lung, breast, or colon cancer) that had stopped responding to standard treatments. The main goals were to check safety…
Phase: PHASE1, PHASE2 • Sponsor: Kineta Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on liver cancer in early trial
Disease control CompletedThis early-phase trial tested a new approach for advanced liver cancer that has not responded to standard treatments. Researchers took participants' own immune cells, modified them in a lab to target a protein called AFP found on cancer cells, and infused them back after a short …
Phase: PHASE1 • Sponsor: Adaptimmune • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug shows promise in helping immune system fight advanced cancers
Disease control CompletedThis study tested a drug called PF-06801591 in 155 people with advanced solid tumors or non-small-cell lung cancer. The drug works by blocking a protein that stops the immune system from attacking cancer cells. The goal was to check safety, how the drug moves through the body, an…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Radiation and immunotherapy combo shows promise in small cancer study
Disease control CompletedThis pilot study tested whether combining high-dose radiation therapy with the immunotherapy drug pembrolizumab (Keytruda) could boost the immune system's ability to fight advanced solid tumors. Twenty-one patients with various advanced cancers received the combination either at …
Phase: PHASE1 • Sponsor: James Larner, MD • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo takes on tough cancers in early trial
Disease control CompletedThis early-phase trial tested a new drug called vilastobart, alone or with another drug (atezolizumab), in 125 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers also looke…
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis phase 1 trial tested the combination of dasatinib (a pill) and bevacizumab (an infusion) in 50 adults with advanced solid tumors that no longer respond to standard treatments. The goal was to find the safest dose and see how well the two drugs work together to slow cancer gr…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug duo shows promise for tough cancers
Disease control CompletedThis study tested two experimental drugs (AK104 and AK117) together, sometimes with chemotherapy, in 128 people with advanced solid tumors. The goal was to see if the combination is safe and can shrink tumors. It focused on patients with stomach, esophageal, or other advanced can…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New cocktail of three drugs tested for tough bladder cancers
Disease control CompletedThis early-phase trial tested a combination of two chemotherapy drugs (gemcitabine and carboplatin) plus lenalidomide, a drug that blocks blood vessel growth in tumors, in 18 adults with advanced solid tumors, especially urothelial (bladder) cancer. The main goal was to find the …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New pill shows promise in shrinking Hard-to-Treat breast tumors
Disease control CompletedThis study tested a new oral drug called BGB-43395 in 33 Chinese patients with advanced or metastatic HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. The goal was to find a safe dose and see if it can shrink tumors wh…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control CompletedThis early-phase study tested a new drug called BGB-C354, alone or with an immunotherapy (tislelizumab), in 63 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check safety and find the right dose. Researchers also looked for…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New shot form of cancer drug tested in 142 patients
Disease control CompletedThis study tested a new under-the-skin shot version of the cancer drug pembrolizumab (Keytruda) in 142 people with advanced solid tumors. The goal was to see how well the body absorbs the drug compared to the standard IV infusion. Researchers also checked for side effects and how…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New vaccine hope for kids with deadly brain tumors
Disease control CompletedThis study tested a special vaccine made from the child's own immune cells (dendritic cells) to fight aggressive brain tumors like high-grade glioma and DIPG. Ten children received the vaccine alongside standard treatments. The goal was to see if the vaccine was safe, possible to…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Experimental drug TdCyd aims to reactivate Tumor-Fighting genes in advanced cancer
Disease control CompletedThis early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for tough leukemia: targeted drug combo shows promise in large trial
Disease control CompletedThis large phase III trial tested whether adding the targeted drug dasatinib to standard chemotherapy improves outcomes for children and young adults with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), including those with certain genetic mutations. Nearly…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New hope for kids with rare kidney cancer: chemo first, then surgery to save kidneys
Disease control CompletedThis study tested giving chemotherapy before surgery to children with Wilms tumor, a rare kidney cancer. The goal was to shrink tumors so surgeons could remove less kidney tissue, helping preserve kidney function. 249 children took part, and the approach aimed to reduce the need …
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
New hope for kids with kidney cancer: tailored treatment may reduce side effects
Disease control CompletedThis phase 3 trial studied how well chemotherapy with or without radiation works after surgery for children with a type of kidney cancer called Wilms tumor. Over 800 children with low- or standard-risk disease took part. The goal was to see if less intensive treatment could still…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Selective immune cell removal may tame transplant complications
Disease control CompletedThis study tested whether removing a specific type of immune cell (naïve T cells) from donor stem cell grafts could prevent graft-versus-host disease (GVHD) after a stem cell transplant for blood cancers. The trial enrolled 84 patients who received high- or medium-intensity chemo…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Protein and exercise combo tested to fight muscle loss in sick kids
Disease control CompletedThis pilot study tested whether giving critically ill children on breathing machines extra protein along with a personalized exercise program could help preserve muscle mass and improve recovery. The trial enrolled 18 children in the ICU and measured how feasible and safe the app…
Phase: NA • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Massive trial seeks best chemo cocktail for kids with leukemia
Disease control CompletedThis large phase 3 trial enrolled over 9,000 children with newly diagnosed standard-risk B-ALL or localized B-LLy. Researchers tested different combinations and doses of chemotherapy drugs to see which worked best with the fewest side effects. The goal was to improve disease-free…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug XTX202 tested in patients with advanced cancers
Disease control CompletedThis study tested a new drug called XTX202 in 95 people with advanced solid tumors that had not responded to standard treatments. The goal was to check safety, find the right dose, and see if the drug could shrink tumors. The trial is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Xilio Development, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New drug cocktail aims to tackle childhood cancers that Won't quit
Disease control CompletedThis early-phase study tested a combination of two drugs, cabozantinib and 13-cis-retinoic acid, in 15 children whose solid tumors had come back or were not responding to standard treatments. The main goal was to find the safest dose and understand side effects. The study did not…
Phase: PHASE1 • Sponsor: Peter Zage • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New drug combo tested for tough cancers
Disease control CompletedThis early-stage trial tested a new drug called AZD6244 combined with standard chemotherapies in 140 people with advanced solid tumors (breast, colon, lung, melanoma, kidney). The main goal was to see if the combination is safe and tolerable, and to find the best dose. Researcher…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Engineered immune cells take aim at tough childhood cancers
Disease control CompletedThis early-phase trial tested whether a new type of immune cell therapy (CD22 CAR T cells) could be safely made and given to 10 children and young adults whose B-cell leukemia or lymphoma had come back or stopped responding to treatment. The therapy uses the patient's own immune …
Phase: PHASE1 • Sponsor: Kara Lynn Davis • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Immune cell boost shows promise against childhood cancers
Disease control CompletedThis early-phase trial tested whether giving activated natural killer (NK) cells, with or without a protein called rhIL15, is safe and feasible for children and young adults with solid tumors that didn't respond to other treatments. Sixteen participants received chemotherapy to l…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug duo aims to tackle Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called TJ004309, either alone or combined with another drug called Toripalimab, in 225 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and see early signs of effectiveness. The…
Phase: PHASE1, PHASE2 • Sponsor: TJ Biopharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug cocktail aims to fight advanced cancers
Disease control CompletedThis early-phase study tested a daily combination of two oral drugs, axitinib and everolimus, in 19 people with advanced solid tumors, particularly kidney cancer. The main goal was to find the safest dose by monitoring side effects in the first month. Researchers also tracked how…
Phase: PHASE1 • Sponsor: University Hospital, Bordeaux • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called HMPL-453 tartrate, either alone or combined with chemotherapy or an immunotherapy (toripalimab), in 190 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Hutchison Medipharma Limited • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested two drugs, cabozantinib and pamiparib, together in 44 people with advanced solid tumors that had stopped responding to standard treatments. The goal was to find the safest dose and understand side effects. The drugs work by blocking certain enzymes t…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called CCT3833 in 31 adults with advanced solid tumours, including melanoma. The main goal was to find a safe dose and check for side effects. Researchers measured how the drug moves through the body and looked for the best dose to use in …
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New cancer drug PM14 enters human testing for advanced tumors
Disease control CompletedThis early-phase trial tested a new drug called PM14 in 126 people with advanced solid tumors that had no standard cure. The main goals were to find a safe dose and check for early signs of tumor shrinkage. The drug was given by IV infusion on different schedules. This is a first…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Experimental COM902 drug shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called COM902, alone or with other drugs, in 94 people with advanced cancers like ovarian, lung, and colon cancer. The main goal was to check safety and find the right dose. Researchers also looked for early signs that the drug m…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Experimental cancer drug injected directly into tumors shows early promise
Disease control CompletedThis early-phase trial tested a new drug called KL340399, which is injected directly into tumors to activate the immune system. It involved 6 adults with advanced solid tumors who had no other treatment options. The main goals were to check safety, find the right dose, and see if…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Experimental cancer drug KL340399 tested in 21 patients
Disease control CompletedThis early-phase trial tested a new drug called KL340399 in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The drug works by activating the STING pathway to help the immune system fight cancer. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Targeted pill shows promise for rare genetic tumor types
Disease control CompletedThis phase 2 study tested the drug erdafitinib in 316 adults and children with advanced solid tumors that have specific FGFR gene mutations or fusions. The main goal was to see if the drug could shrink tumors. Participants took erdafitinib tablets daily. The study is now complete…
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New cancer drug HBM1020 tested in tiny early trial
Disease control CompletedThis early-phase study tested a new drug, HBM1020, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. The drug was given by IV every three weeks. Because this is a Phase 1 trial, i…
Phase: PHASE1 • Sponsor: Harbour BioMed US, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Experimental drug PRL3-ZUMAB shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called PRL3-ZUMAB in 14 people with advanced solid tumors (like stomach or liver cancer) that stopped responding to standard treatments. The drug was given every two weeks to see if it could shrink tumors or stop them from growing. Researchers also lo…
Phase: PHASE2 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New ALK inhibitor ensartinib tested in first human trial for lung cancer
Disease control CompletedThis study tested a new oral drug called ensartinib (X-396) for the first time in humans. It involved 131 people with advanced solid tumors, including those with ALK-positive non-small cell lung cancer. The goal was to find the safest dose and see if the drug could shrink tumors.…
Phase: PHASE1, PHASE2 • Sponsor: Xcovery Holdings, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Radioactive drug shows promise against advanced cancers
Disease control CompletedThis study tested a new radioactive drug, 177Lu-NeoB, in 35 adults with advanced solid tumors that have a specific marker (GRPR). The goal was to check safety, find the best dose, and see if it shrinks tumors. It is an early-stage trial, so it focuses on safety and dosing, not a …
Phase: PHASE1, PHASE2 • Sponsor: Advanced Accelerator Applications • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two cancer drugs, bortezomib and clofarabine, in 28 adults with advanced solid tumors, lymphomas, or myelodysplastic syndromes that had stopped responding to standard therapy. The main goal was to find the safest dose and check for s…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called AZD8186 combined with the chemotherapy docetaxel in 23 patients with advanced solid tumors that have PTEN or PIK3CB gene mutations. The main goal was to find the safest dose and understand side effects. The study is complete, but re…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Experimental antibody HH-101 tested in 12 patients with advanced cancers
Disease control CompletedThis early-stage trial tested an experimental drug called HH-101 in 12 people with advanced solid tumors that had not responded to standard treatments. The main goal was to check the drug's safety and find the right dose. Participants received HH-101 as an IV infusion every three…
Phase: PHASE1 • Sponsor: Huahui Health • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control CompletedThis completed phase I/IIb trial tested a personalized vaccine made from each patient's unique tumor mutations. Eight adults with advanced solid tumors or high recurrence risk received the vaccine alongside an immune booster and later checkpoint inhibitors. The goal was to see if…
Phase: PHASE1, PHASE2 • Sponsor: Seqker Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug targets tough childhood cancers with genetic flaws
Disease control CompletedThis phase 2 trial tested the drug samotolisib in 18 children and young adults with advanced solid tumors, non-Hodgkin lymphoma, or histiocytic disorders that had spread, returned, or stopped responding to treatment. Only patients whose tumors had specific mutations in the TSC or…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cancer drug shows promise in early trial for Tough-to-Treat tumors
Disease control CompletedThis study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…
Phase: PHASE1, PHASE2 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for tough childhood leukemia
Disease control CompletedThis early-phase study tested whether adding the targeted drug palbociclib to standard chemotherapy is safe for children with acute lymphoblastic leukemia that has returned or not responded to treatment. Only 2 children took part, and the main goal was to find the highest tolerab…
Phase: PHASE1 • Sponsor: Tanja Andrea Gruber • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New drug tested for advanced cancers: early results
Disease control CompletedThis early-phase trial tested a new drug called NOV140101 in 32 adults with advanced solid tumors that had spread or could not be removed by surgery. The main goals were to find the safest dose and check for side effects. The study is complete, but it was too small to determine i…
Phase: PHASE1 • Sponsor: Idience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New Two-Step transplant shows promise for blood cancer patients
Disease control CompletedThis study tested a two-step stem cell transplant for people with blood cancers like leukemia and lymphoma. First, patients received low-dose chemotherapy and radiation to prepare their bodies. Then, they got donor stem cells followed by drugs to prevent the donor cells from atta…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New Double-Action antibody shows promise against Hard-to-Treat cancers
Disease control CompletedThis phase 2 trial tested an experimental drug called HX009 in 20 adults with advanced solid tumors that had stopped responding to standard treatments. HX009 is a bifunctional antibody designed to block two proteins (CD47 and PD-1) that help tumors hide from the immune system. Th…
Phase: PHASE2 • Sponsor: Hangzhou Hanx Biopharmaceuticals, Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Triple-Drug immunotherapy cocktail shows promise in advanced tumors
Disease control CompletedThis early-phase trial tested whether combining the experimental drug relatlimab with other immunotherapies (nivolumab plus either BMS-986205 or ipilimumab) is safe and can shrink tumors in people with advanced solid cancers. A total of 229 participants with various incurable, ad…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Targeted drug shows promise for kids with tough cancers
Disease control CompletedThis study tested a drug called palbociclib in 23 children and young adults (ages 1–21) whose cancers had come back or didn't respond to treatment. The drug works by blocking proteins that help cancer cells grow. The goal was to see if it could shrink tumors or slow the disease i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New hope for Hard-to-Treat cancers? utidelone trial underway
Disease control CompletedThis phase 2 trial tests the drug utidelone in 126 people with advanced solid tumors (excluding breast, lung, and colorectal cancers) that have not responded to standard treatments. The study aims to see if the drug can shrink tumors and how safe it is. Participants receive utide…
Phase: PHASE2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Triple immunotherapy cocktail shows promise against tough cancers
Disease control CompletedThis study tested combinations of three immunotherapy drugs—tislelizumab, surzebiclimab, and alcestobart—in 147 adults with advanced solid tumors that had not responded to prior treatments. The goal was to find safe doses and see if the drugs could shrink tumors. The trial is now…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Diabetes drug plus chemo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested the safety of combining pioglitazone (a diabetes drug) with carboplatin (a chemotherapy) in 14 people with advanced solid tumors that could not be cured with standard treatments. The goal was to find the best dose and see if the combination is safe. …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Early trial checks safety of experimental cancer drug
Disease control CompletedThis early-phase study tested a new drug called BAT4706 in 28 adults with advanced solid tumors or melanoma who had no other good treatment options. The main goal was to find a safe dose and check for side effects. This was not a cure study; it aimed to gather safety information …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New pill shows promise against advanced cancers in early trial
Disease control CompletedThis study tested a new cancer drug called brigimadlin (BI 907828) in 266 adults with advanced solid tumors that had spread or stopped responding to standard treatments. The goal was to find a safe dose and see if the drug could shrink tumors. Brigimadlin is an MDM2 inhibitor tak…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Generic cancer pill matches Brand-Name drug in study
Disease control CompletedThis study checked if a generic version of the cancer drug trifluridine/tipiracil works the same as the brand-name drug Lonsurf in 76 patients with solid tumors. Participants took the drug under fasting and fed conditions to compare how the body absorbs it. The goal was to show t…
Phase: NA • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a new drug called DF6215, alone or with another drug (pembrolizumab), in 35 adults with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to find the safest dose and check for side effects. The study is com…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New cancer drug ZN-c3 shows early promise in solid tumor trial
Disease control CompletedThis early-phase study tested a new drug called ZN-c3 (Azenosertib) in 274 adults with various solid tumors. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug could shrink tumors. This is a first step to see if the…
Phase: PHASE1 • Sponsor: K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New immunotherapy combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called DF6002, either alone or combined with the approved immunotherapy nivolumab (Opdivo), in 170 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find th…
Phase: PHASE1 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug targets Hard-to-Treat cancers in early trial
Disease control CompletedThis study tested a new drug called DF1001 in 270 adults with advanced solid tumors that have spread or cannot be removed. The drug works by helping the body's immune cells attack cancer cells. The trial first found the safest dose, then tested it alone or with other cancer drugs…
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New pill takes on stomach cancer in first human trial
Disease control CompletedThis study tested a new drug called BI 3706674 in 47 adults with advanced stomach or esophageal cancer that had not responded to prior treatment. The drug is a tablet that blocks growth signals in cancer cells. The main goals were to find a safe dose and see if the drug could shr…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New combo therapy tested for deadly childhood brain cancer
Disease control CompletedThis early-phase study tested whether adding the drug cilengitide to standard radiation is safe for children and young adults with a rare, aggressive brain tumor called DIPG. The main goal was to find the highest safe dose. 32 participants were enrolled. The study did not aim to …
Phase: PHASE1 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
New cancer drug RS-0139 tested in humans for first time
Disease control CompletedThis early-phase trial tested a new drug called RS-0139 in 16 people with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to target tumors specifically, and the main goals were to find a safe dose and understand how the body processe…
Phase: PHASE1 • Sponsor: RS Arastirma Egitim Danismanlik Ilac Sanayi Ticaret A.S. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New Two-Drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—NT-I7 (efineptakin alfa) and pembrolizumab (Keytruda)—in 215 people with advanced solid tumors that had stopped responding to treatment. The goal was to check safety, find the right dose, and see if the combo could shrink tumors. The t…
Phase: PHASE1, PHASE2 • Sponsor: NeoImmuneTech • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus engineered to fight cancer shows promise in early trial
Disease control CompletedThis early-stage trial tested a modified virus called TILT-123 in 32 people with advanced solid tumors that had not responded to standard treatments. The virus is designed to infect and kill cancer cells while releasing immune-boosting proteins. The main goal was to check safety …
Phase: PHASE1 • Sponsor: TILT Biotherapeutics Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested the safety of combining two drugs—AZD1775 (a pill) and durvalumab (an IV infusion)—in 56 adults with advanced solid tumours that had stopped responding to standard treatments. The goal was to find safe doses and watch for side effects. While not a cu…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Epigenetic and immune drugs join forces against tough tumors
Disease control CompletedThis completed Phase 2 trial tested whether combining an immunotherapy drug (durvalumab) with an epigenetic drug (tazemetostat) can control advanced solid tumors like pancreatic, colorectal, and soft-tissue sarcoma. The study enrolled 164 adults and measured how well the combo sh…
Phase: PHASE2 • Sponsor: Institut Bergonié • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug cocktail shows promise against tough cancers
Disease control CompletedThis study tested a combination of two experimental drugs, AK112 and AK117, with or without chemotherapy, in 154 people with advanced solid tumors. The goal was to see if the combo could shrink tumors and control the disease. The trial has finished, and researchers are now lookin…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for kids with resistant cancers? drug combo shows promise in early trial
Disease control CompletedThis study tested the safety and effectiveness of the drug abemaciclib combined with other cancer medicines in 47 children and young adults whose solid tumors (including neuroblastoma) had stopped responding to standard treatments. The goal was to find the best dose and see if th…
Phase: PHASE1, PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New shot aims to stop Chemo's dangerous side effect
Disease control CompletedThis early-stage trial tested a new drug called PN20 in 24 adults with lymphoma or solid tumors who were getting chemotherapy. The goal was to see if a single injection before chemo could safely prevent a drop in platelets, which can cause bleeding. Researchers checked safety and…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New targeted pill shows promise for Hard-to-Treat bile duct cancers
Disease control CompletedThis study tested a new oral drug called RLY-4008 in 490 adults with advanced bile duct cancer or other solid tumors that have specific FGFR2 gene changes. The drug is designed to block the FGFR2 protein, which can drive cancer growth. The trial aimed to find the safest dose and …
Phase: PHASE1, PHASE2 • Sponsor: Elevar Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New combo shows promise in controlling advanced cancers
Disease control CompletedThis study tested an experimental drug (BMS-986253) combined with standard immunotherapy drugs (nivolumab with or without ipilimumab) in 281 people with advanced cancers like melanoma. The main goals were to check safety and see if tumors shrank. This is a disease-control approac…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
New drug cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BGB-10188, alone or combined with other cancer drugs (zanubrutinib for blood cancers, tislelizumab for solid tumors), in 97 patients whose cancers had returned or stopped responding to treatment. The main goals were to find safe dos…
Phase: PHASE1, PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy shows promise for hard-to-treat childhood cancers
Disease control CompletedThis early-stage study tested a mix of two drugs (pembrolizumab and decitabine) plus targeted radiation in 22 children and young adults whose solid tumors or lymphoma had returned or stopped responding to treatment. The main goals were to see if the combination was safe and toler…
Phase: EARLY_PHASE1 • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested two or three drugs together in adults with advanced solid tumors (cancers that have spread). The main goal was to find the safest dose and see if the combination can shrink tumors. Participants took brigimadlin pills and received ezabenlimab infusions every 3 we…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New pill targets brain tumors with IDH mutations
Disease control CompletedThis early-phase study tested an oral drug called AG-881 in 95 adults with advanced solid tumors, including brain tumors (gliomas), that have specific IDH gene mutations. The main goals were to check safety, find the best dose, and see how the drug works in the body. While not a …
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug AMG 305 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 305 in 37 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Participants received the drug and were mo…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New chemo regimen shows promise for childhood leukemia
Disease control CompletedThis study looked back at 320 children with acute myeloid leukemia (AML) who received one of two chemotherapy regimens between 2005 and 2015. The newer approach used a risk-based strategy and more intensive chemotherapy. Researchers compared survival, relapse, and remission rates…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New hope for kids with resistant tumors? early trial tests CUDC-907
Disease control CompletedThis early-phase study tested a new drug called CUDC-907 in 26 children and young adults (ages 1-21) with cancers that had come back or stopped responding to treatment, including solid tumors, brain tumors, and lymphoma. The main goal was to find a safe dose and check for side ef…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New oral drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested two experimental drugs, FdCyd and THU, taken by mouth for advanced solid tumors that had not responded to standard treatments. Fifty-nine adults received the drugs in 21-day cycles to see if they were safe and tolerable. The goal was to find a dose f…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new pill called larotrectinib in 75 adults with advanced cancers that have a specific gene change (NTRK fusion). The main goals were to check the drug's safety, find the best dose, and see how the body processes it. Participants had no other good treatment opt…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New cancer pill tested in humans for first time
Disease control CompletedThis early-stage trial tested a new oral drug, MSP008-22, in 7 adults with advanced solid tumors (breast, ovarian, prostate, head and neck cancers) that had spread or could not be removed. The main goal was to find a safe dose and check for side effects. This is a first step to s…
Phase: PHASE1 • Sponsor: Godavari Biorefineries Limited • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BI 754091 in 110 people with advanced solid tumours that had spread or could not be removed surgically. The main goals were to find the safest dose and check for side effects. Researchers also looked for early signs th…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New nanoparticle chemo shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new drug called SNB-101 in 21 people with advanced solid tumors (like colorectal, breast, and lung cancers) that had stopped responding to standard treatments. SNB-101 is a nanoparticle version of SN-38, the active part of a common chemotherapy dru…
Phase: PHASE1 • Sponsor: SN BioScience • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New injection attacks tumors from inside out
Disease control CompletedThis early-stage trial tested an experimental drug called CyPep-1, injected directly into tumors, either alone or with the immunotherapy pembrolizumab. The study involved 60 adults with advanced solid cancers that had stopped responding to standard treatments. The main goals were…
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in controlling Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called VS-6766, given alone or with everolimus, in 104 adults with advanced solid tumors or multiple myeloma that had stopped responding to standard treatments. The goal was to find a safe, tolerable dosing schedule and measure h…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New hope for tough cancers: revumenib trial shows promise
Disease control CompletedThis early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…
Phase: PHASE1, PHASE2 • Sponsor: Syndax Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy shows promise for Hard-to-Treat cancers
Disease control CompletedThis study tested a new immunotherapy drug, ezabenlimab, combined with other cancer medicines in 211 adults with advanced solid tumors that had spread. The goal was to see if the tumors shrank or disappeared. Participants received different drug combinations, and doctors monitore…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in Hard-to-Treat cancers
Disease control CompletedThis study tested two experimental drugs (BI 754111 and BI 754091) that help the immune system attack cancer. It included 172 adults with advanced solid tumors, including non-small cell lung cancer that had returned after prior treatment. The first part found the safest dose, and…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:15 UTC
-
Experimental CAR-T therapy targets Hard-to-Treat solid tumors
Disease control CompletedThis pilot study tested a new type of immune cell therapy called anti-ALPP CAR-T cells in 5 patients with advanced solid tumors that have a specific marker (ALPP). The goal was to see if the treatment is safe and can shrink tumors. Patients first received chemotherapy to prepare …
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Experimental immune therapy takes aim at Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new type of immunotherapy called ALPP CAR-T cells in 5 adults with advanced solid tumors that had not responded to standard treatments. The therapy involves genetically modifying a patient's own immune cells to recognize and attack cancer cells tha…
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Experimental combo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested an experimental drug called BMS-986288, both by itself and combined with the immunotherapy nivolumab (Opdivo), in 219 people with advanced solid tumors that had worsened after standard treatments. The main goal was to check safety and tolerability, a…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Drug combo shows promise for tough cancers
Disease control CompletedThis early-phase trial tested a combination of two drugs—pembrolizumab (an immunotherapy) and nintedanib (a drug that blocks blood vessel growth)—in 196 adults with advanced solid tumors that had worsened after standard treatment. The main goal was to find the safest dose of nint…
Phase: PHASE1 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
Chemo-Immuno cocktail shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested whether adding two chemotherapy drugs (6-mercaptopurine and 6-thioguanine) to an immunotherapy drug (Atezolizumab) could help treat advanced solid tumors that have stopped responding to standard treatments. The study enrolled 18 adults with metastati…
Phase: PHASE1, PHASE2 • Sponsor: Kristoffer Rohrberg • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for kids with rare cancers: targeted drug shows promise
Disease control CompletedThis study tested a drug called avapritinib in 29 children aged 2 to 18 with advanced solid tumors that have specific genetic changes (KIT or PDGFRA). The goal was to see if the drug is safe and can shrink or control the tumors. Participants took the drug by mouth, and researcher…
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New drug shows promise for Hard-to-Treat cancers with p53 gene
Disease control CompletedThis study tested a new drug called ALRN-6924 in 142 people with advanced solid tumors or lymphomas that have a normal p53 gene. The goal was to see if the drug is safe and can shrink tumors. Participants had cancers that did not respond to standard treatments or had no standard …
Phase: PHASE1, PHASE2 • Sponsor: Aileron Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New drug JAB-8263 tested in patients with advanced cancers
Disease control CompletedThis early-phase study tested a new drug called JAB-8263 in 41 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study is now complete.
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New cancer drug MRX-2843 enters first human trial
Disease control CompletedThis early-stage trial tested a new drug called MRX-2843 in 42 adults with advanced solid tumors that had spread or come back after other treatments. The main goal was to check safety and find the right dose. Researchers monitored side effects and how the drug moved through the b…
Phase: PHASE1 • Sponsor: Meryx, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Experimental antibody combo tackles Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called ADG116, which helps the immune system attack cancer cells. The study included 72 adults with advanced solid tumors that had stopped responding to standard treatments. Some participants received ADG116 alone, while others g…
Phase: PHASE1 • Sponsor: Adagene Inc • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise in early trial for kids with deadly brain cancer
Disease control CompletedThis early-phase study tested an experimental drug called INCB7839 in 13 children whose high-grade gliomas (aggressive brain tumors) had come back or worsened after standard treatment. The main goals were to find a safe dose and check for side effects. The drug works by blocking …
Phase: PHASE1 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New immune booster FL115 tested in patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called FL115 in 18 adults with advanced solid tumors that had stopped responding to standard treatments. FL115 is designed to strengthen the body's immune cells to fight cancer. The main goal was to check safety and find the right dose, wh…
Phase: PHASE1 • Sponsor: Suzhou Forlong Biotechnology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug IBI334 tested on 28 patients with advanced cancer
Disease control CompletedThis study tested a new drug called IBI334 in 28 people with advanced solid tumors that could not be removed by surgery or had spread. The main goals were to check the drug's safety and see if it helps control the cancer. The study is now complete.
Phase: PHASE1, PHASE2 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug ZGGS15 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested a new biologic drug called ZGGS15 in 22 adults with advanced solid tumors who had no standard treatment options left. The main goals were to check safety, find the right dose, and look for early signs that the drug might control tumor growth. Partici…
Phase: PHASE1 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Triple-Drug cocktail shows promise against advanced liver cancer
Disease control CompletedThis study looked at whether adding a mix of three drugs (thalidomide, carmofur, and a traditional Chinese medicine) to a standard procedure called TACE helps people with advanced liver cancer live longer. The study involved 545 patients and compared the combination treatment to …
Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called JAB-BX102, alone or with the immunotherapy pembrolizumab, in 21 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also …
Phase: PHASE1, PHASE2 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called BAT8006 in 216 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the best dose for future studies. This is not a cure, but a step toward better control…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New pill shows promise in early trial for tough cancers
Disease control CompletedThis early-phase study tested an experimental oral drug called Q702 in 51 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects, while also looking at whether the drug could shrink …
Phase: PHASE1 • Sponsor: Qurient Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Heat and immune boost: new combo tackles Hard-to-Treat cancers
Disease control CompletedThis trial tested a two-step treatment for people with advanced solid tumors that no longer respond to standard therapies. First, a laser heats and destroys part of the tumor. Then, a drug called IP-001 is injected directly into the treated area to help the immune system recogniz…
Phase: PHASE1, PHASE2 • Sponsor: Swiss Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
Liver cancer drug safety checked in 263 patients
Disease control CompletedThis study looked at side effects of the drug Cabometyx in 263 Japanese adults with advanced liver cancer that had worsened after other treatments. Doctors monitored participants for 12 months to record any serious or severe side effects. The goal was to understand the drug's saf…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New pill JAB-3312 tested in patients with advanced cancers
Disease control CompletedThis early-stage trial tested an oral drug called JAB-3312 in 40 adults with advanced solid tumors (like lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked …
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New cancer pill shows promise in early trial
Disease control CompletedThis early-phase study tested a new oral drug called LP-118 in 68 people with advanced solid tumors or lymphomas that had stopped responding to standard treatments. LP-118 works by blocking two proteins that help cancer cells survive. The main goals were to find a safe dose and c…
Phase: PHASE1 • Sponsor: Guangzhou Lupeng Pharmaceutical Company LTD. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis phase 1 study tested an experimental drug called LY3039478 in 247 people with advanced or metastatic cancer, including lymphoma. The main goal was to find a safe dose and see how the drug affects the body. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug NB003 tested in 258 patients with advanced cancers
Disease control CompletedThis early-phase trial tested a new drug called NB003 in 258 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it could shrink tumors. The study is now complete, an…
Phase: PHASE1 • Sponsor: Ningbo Newbay Technology Development Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug RC88 shows promise for advanced cancers in early trial
Disease control CompletedThis study tested an injectable drug called RC88 in 41 people with advanced solid tumours who had no other good treatment options. The main goal was to check the drug's safety and find the right dose. The study is now complete, and results will help guide future research.
Phase: PHASE1, PHASE2 • Sponsor: RemeGen Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New pill shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new daily pill, ASC61, in 18 adults with advanced solid tumors that had stopped responding to standard treatments. The goal was to check the drug's safety and how the body processes it. Researchers looked for side effects and measured tumor respons…
Phase: PHASE1 • Sponsor: Ascletis Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New cancer drug shows promise in early human trial
Disease control CompletedThis early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effect…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo tested for advanced cancers in asian patients
Disease control CompletedThis early-phase trial tested an experimental drug called ezabenlimab, alone or combined with another drug (BI 754111), in 146 Asian patients with advanced solid tumors. The main goals were to check safety, find the right dose, and see if the combination shrinks tumors in cancers…
Phase: EARLY_PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested a new drug called RO7623066, given alone or with other treatments, in 116 adults with advanced solid tumors that had not responded to prior therapies. The main goals were to find the safest dose and check for side effects. While not a cure, the study…
Phase: PHASE1 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
New drug combo shows promise against tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986315, alone or combined with other immunotherapies (nivolumab or cetuximab), in 44 people with advanced solid tumors like head and neck, lung, or kidney cancer. The main goals were to check safety and find the right …
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New drug E7090 tested in patients with advanced solid tumors
Disease control CompletedThis early-phase study tested an experimental drug called E7090 in 40 adults with advanced solid tumors that had not responded to standard treatments. The goal was to find the safest dose and check for early signs of effectiveness, especially in patients whose tumors have certain…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New cancer drug ABBV-155 enters first human tests
Disease control CompletedThis early-phase study tested a new drug called ABBV-155, given alone or with standard chemotherapy (paclitaxel or docetaxel), in 168 adults with advanced solid tumors that had come back or stopped responding to treatment. The main goal was to find a safe dose and check for early…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New antibody drug tested in patients with Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called BAT6026 in 30 adults with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked at how the drug moves through the body …
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New cancer drug shows promise in early safety trial
Disease control CompletedThis early-stage study tested a new drug called BAT1308 in 59 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. Researchers also looked at how the drug moves through the body. Th…
Phase: PHASE1 • Sponsor: Bio-Thera Solutions • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
New immunotherapy cocktail shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-stage study tested a fixed-dose combination of two immunotherapy drugs (relatlimab and nivolumab) in 24 Chinese patients with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, how the drugs move through the b…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug duo shows early promise against advanced cancers
Disease control CompletedThis early-phase study tested a combination of two experimental drugs (AK127 and AK104) in 67 people with advanced or metastatic solid tumours that had stopped responding to standard treatments. The main goals were to check safety and find the right dose, while also looking for s…
Phase: EARLY_PHASE1 • Sponsor: Akesobio Australia Pty Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New cancer drug GEN1056 tested in first human trial
Disease control CompletedThis early-stage trial tested a new drug, GEN1056, in 26 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose. Researchers also looked for signs that the drug might shrink tumors.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Could less radiation be enough? new trial tests tailored therapy for kids with brain tumors
Disease control CompletedThis phase 2 trial tested whether children with localized central nervous system germ cell tumors could safely receive lower doses of radiation after chemotherapy. The study enrolled 262 children and used response to chemotherapy to decide the radiation dose. The goal was to main…
Phase: PHASE2 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New cancer drug BR101 enters first human tests
Disease control CompletedThis early-phase trial tested a new drug called BR101 in 15 people with advanced solid tumors that had not responded to standard treatments. The main goals were to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receiv…
Phase: PHASE1 • Sponsor: BioRay Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New immunotherapy combo shows promise for advanced cancers
Disease control CompletedThis study tested an experimental drug called BMS-986249, either alone or combined with the immunotherapy nivolumab (Opdivo), in 356 people with advanced solid tumors. The main goals were to check safety and find the right dose. Researchers also looked at whether the tumors shran…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New triple therapy shows promise for resistant cancers
Disease control CompletedThis early-phase trial tested a combination of three drugs—afuresertib, sintilimab, and chemotherapy—in 22 adults with solid tumors (including lung, cervical, and stomach cancers) that had stopped responding to prior immunotherapy. The goal was to find a safe dose and see if the …
Phase: PHASE1, PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, alone or combined with atezolizumab (Tecentriq), in 40 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and see if t…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase trial tested a new immunotherapy drug called BDB001, both alone and combined with pembrolizumab, in 87 adults with advanced solid tumors that had progressed after standard treatments. The main goals were to check safety and find the best dose. The study is comple…
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Early trial of BDB018 combo for tough cancers wraps up with just one patient
Disease control CompletedThis early-phase study tested a new immunotherapy drug called BDB018, given alone or with pembrolizumab, in people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to check safety and find the right dose. Only one person took part, …
Phase: PHASE1 • Sponsor: Eikon Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New antibody drug takes on Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a new drug called CHS-388 in 145 people with advanced solid tumors (kidney, liver, or lung cancer) that had stopped responding to standard treatments. CHS-388 is an antibody that blocks a protein called IL-27, which may help the immune system fight c…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-phase study tested a new drug called boserolimab (MK-5890), either alone or combined with the immunotherapy pembrolizumab (KEYTRUDA), in 182 adults with advanced solid tumors, including lung and breast cancers. The main goals were to check safety and how the drug moves…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug aims to boost immune system against tough cancers
Disease control CompletedThis early-phase trial tested a new drug called HCW9218 in 18 people with advanced solid tumors that had not responded to at least two prior treatments. The drug is designed to both activate immune cells and block signals that help tumors grow. The main goal was to find a safe do…
Phase: PHASE1 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Cancer drug tazemetostat gets Long-Term safety check in rollover trial
Disease control CompletedThis study offers continued access to tazemetostat for 58 people with various cancers who already benefited from the drug in earlier trials. The main goal is to monitor long-term safety and side effects. Participants must have shown clinical benefit from tazemetostat before joini…
Phase: PHASE1, PHASE2 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis study tested a two-step stem cell transplant for people with high-risk blood cancers like leukemia and lymphoma. First, patients got low-dose chemotherapy and radiation to prepare the body. Then, they received donor stem cells and immune cells to help destroy remaining cance…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New immunotherapy DF9001 targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called DF9001, which helps the body's natural killer cells attack cancer cells. It was given alone or with another immunotherapy (pembrolizumab) to 24 adults with advanced solid tumors that have the EGFR protein. The goal was to check safety and find …
Phase: PHASE1, PHASE2 • Sponsor: Dragonfly Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New combo therapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control CompletedThis study tested a new oral drug called RP-3500 (camonsertib), alone or combined with talazoparib or gemcitabine, in 276 adults with advanced solid tumors that have certain genetic mutations. The main goals were to find the safest dose and check for early signs of tumor shrinkag…
Phase: PHASE1, PHASE2 • Sponsor: Repare Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
Experimental liposomal chemo shows promise in kids with relapsed leukemia
Disease control CompletedThis pilot study tested a liposomal form of the chemotherapy drug vincristine (Marqibo) combined with standard UK ALL R3 chemotherapy in 29 children, adolescents, and young adults with relapsed acute lymphoblastic leukemia. The main goal was to see if it was safe and tolerable at…
Phase: PHASE1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase study tested a new drug called BAY 2862789 in 45 people with advanced solid tumors, including non-small cell lung cancer. The drug works by activating immune cells to fight cancer. The main goals were to check safety, find the best dose, and see how the drug move…
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC
-
New antibody combo tested in advanced cancer patients
Disease control CompletedThis early-phase trial tested a new antibody drug called AGEN1777, given alone or with another antibody (a PD-1 inhibitor), in 25 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and se…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a new antibody called HMBD-002, given alone or with pembrolizumab, in 48 adults with advanced solid tumors (like lung or breast cancer) that had stopped responding to standard treatments. The main goals were to check safety, find the best dose, and s…
Phase: PHASE1 • Sponsor: Hummingbird Bioscience • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Exercise may reverse chemo heart damage in childhood cancer survivors
Disease control CompletedThis study looked at whether a 3-month aerobic exercise program could improve heart function in 47 childhood cancer survivors who had been treated with anthracycline chemotherapy. Participants chose their own exercise and received support at a YMCA. The goal was to see if exercis…
Sponsor: Connecticut Children's Medical Center • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested a combination of two experimental drugs, vobramitamab duocarmazine and lorigerlimab, in 31 people with advanced solid tumors like prostate, melanoma, and pancreatic cancer. The main goal was to check safety and find the right dose. Participants recei…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early trial for advanced cancers
Disease control CompletedThis early-phase study tested an experimental drug called MK-4830, either by itself or combined with other cancer therapies like pembrolizumab, in 470 people with advanced solid tumors. The main goals were to check safety, find the right dose, and see if tumors shrank. The study …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug combo shows promise in early cancer trial
Disease control CompletedThis early-stage study tested a new drug (BI 836880) alone and with another drug (BI 754091) in 21 Japanese patients with advanced solid tumors. The main goal was to find the safest dose and check for side effects. This is not a cure, but a step toward better controlling advanced…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New drug AMG 256 tested in patients with hard-to-treat cancers
Disease control CompletedThis early-phase study tested a new drug called AMG 256 in 34 adults with advanced solid tumors that could not be cured by standard treatments. The main goals were to check the drug's safety and find the best dose for future studies. Researchers monitored side effects and how the…
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Can eating only 8 hours a day help childhood cancer survivors fight obesity?
Disease control CompletedThis study tested whether eating only during an 8-hour window each day (time-restricted eating) helps young adult survivors of childhood cancer manage their weight. Thirteen survivors participated to see if this approach is safe, doable, and acceptable. The goal is to reduce obes…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New drug combo aims to boost immune system against Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of two immunotherapy drugs, BGB-A445 and tislelizumab, in 204 people with advanced solid tumors including lung, head and neck, and nasopharyngeal cancers. The main goals were to check safety and find the best dose. The trial is now comp…
Phase: PHASE1 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Experimental drug combo takes on tough cancers
Disease control CompletedThis early-phase trial tested an experimental drug called BMS-986408, alone or combined with the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), in 68 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to chec…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New hope for young cancer patients: drug shows promise against tough tumors
Disease control CompletedThis study tested the drug lenvatinib in 127 children, adolescents, and young adults whose solid tumors had come back or stopped responding to treatment. The goal was to see if the drug could shrink tumors and to check for side effects. Participants received lenvatinib daily, and…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
Proton beam zaps liver tumors: new hope for cancer patients?
Disease control CompletedThis study tested a precise type of radiation called proton beam therapy for people whose cancer has spread to the liver. 92 adults with 1 to 4 liver tumors received this treatment. The goal was to see if it could stop tumor growth and cause fewer side effects than standard radia…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows promise in early trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 24 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find the safest dose and check for side effects. Researchers also looked at how the drug moves through the bo…
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug shows early promise in small safety trial
Disease control CompletedThis early-phase trial tested a new drug called BI 836880 in 29 adults with advanced solid tumors that had not responded to standard treatments. The main goal was to find a safe dose and check for side effects. The study was not designed to cure cancer, but to gather information …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer drug combo shows promise in early trial
Disease control CompletedThis early-phase trial tested two experimental drugs, BNT152 and BNT153, alone and together in 86 adults with advanced solid tumors that had spread or could not be removed and had no standard treatment options. The main goal was to check safety and find the best dose. Researchers…
Phase: PHASE1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New cancer cocktail shows promise in early human trial
Disease control CompletedThis early-phase study tested an experimental drug called ABBV-CLS-579, given alone or with other cancer treatments, in 101 adults with advanced solid tumors that had stopped responding to standard therapy. The main goal was to find safe and tolerable doses, not to prove the drug…
Phase: PHASE1 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Triple-Drug cocktail shows promise in Hard-to-Treat cancers
Disease control CompletedThis early-phase study tested a combination of three drugs—selinexor, nivolumab, and ipilimumab—in 11 adults with advanced or metastatic solid tumors that had stopped responding to standard treatments. The main goal was to check the safety and tolerability of the combination, whi…
Phase: PHASE1 • Sponsor: National University Hospital, Singapore • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
New drug aims to wipe out hidden leukemia cells before they return
Disease control CompletedThis study tested a drug called blinatumomab in 36 adults with B-cell acute lymphoblastic leukemia who were in remission but still had tiny amounts of cancer cells detectable (minimal residual disease). The goal was to see if the drug could clear those leftover cells and improve …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Can better nutrition help kids beat cancer?
Disease control CompletedNearly 60% of children with cancer become malnourished, which can lead to infections and worse outcomes. This pilot study tested three nutrition approaches—oral supplements, appetite-stimulating drugs, and tube feeding—in 19 children to see which best improved body composition an…
Phase: PHASE2, PHASE3 • Sponsor: Corey Hawes • Aim: Disease control
Last updated Jun 26, 2026 17:40 UTC
-
Immunotherapy combo shows promise for chinese cancer patients
Disease control CompletedThis study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 37 Chinese patients with advanced solid tumors that had not responded to prior treatment. The main goals were to check safety and see if the drugs could shrink tumors. The trial is now comple…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 26, 2026 17:18 UTC
-
New combo therapy targets Hard-to-Treat tumors
Disease control CompletedThis early-phase trial tested a new drug called RiMO-301, injected directly into tumors, along with standard radiation. It involved 32 people with advanced cancers that could not be cured. The main goal was to find a safe dose and check for any early signs of tumor shrinkage.
Phase: PHASE1 • Sponsor: Coordination Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 26, 2026 17:16 UTC
-
Precision proton beam aims to zap liver tumors with fewer side effects
Disease control CompletedThis study tested proton beam radiation, a highly targeted form of radiotherapy, in 83 people with liver cancer that could not be surgically removed. The goal was to see if this precise approach could control tumors while reducing damage to healthy tissue. Participants received d…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 26, 2026 17:05 UTC
-
New pill plus immunotherapy shows promise in early cancer trial
Disease control CompletedThis early-phase study tested an experimental drug called TPST-1495, taken as a pill, either alone or combined with the immunotherapy Keytruda (pembrolizumab). The trial included 89 people with advanced solid tumors like colorectal, lung, head and neck, and endometrial cancers wh…
Phase: PHASE1 • Sponsor: Tempest Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 15:48 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental drug called LM-108, alone or combined with another immunotherapy, in 78 people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety and find the right dose. Researchers als…
Phase: PHASE1, PHASE2 • Sponsor: LaNova Australia Pty Limited • Aim: Disease control
Last updated Jun 26, 2026 15:31 UTC
-
New radioactive therapy shows promise in early trial for tough cancers
Disease control CompletedThis early-phase trial tested a new radioactive drug called 177Lu-LNC1004 in 11 adults with advanced solid tumors that had stopped responding to standard treatments. The drug targets a protein (FAP) found on many cancer cells, delivering radiation directly to the tumor. The main …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Disease control
Last updated Jun 26, 2026 15:15 UTC
-
Could a malaria drug help fight liver cancer?
Disease control CompletedThis study tested whether adding hydroxychloroquine (a malaria drug) to the standard cancer drug sorafenib could slow tumor growth in people with advanced liver cancer. 64 adults who were not candidates for surgery or transplant took part. The goal was to see if the combination d…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Disease control
Last updated Jun 26, 2026 14:14 UTC
-
Experimental Vaccine-Like therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-phase trial tested an experimental immunotherapy called ELI-002 in 25 people with KRAS-mutated pancreatic, colorectal, lung, ovarian, or bile duct cancers who had signs of remaining disease after standard treatment. The therapy aims to train the immune system to attack…
Phase: PHASE1 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jun 26, 2026 13:30 UTC
-
New cancer drug EVT801 tested in humans for first time
Disease control CompletedThis early-stage trial tested an experimental drug called EVT801 in 32 adults with advanced solid tumours that had stopped responding to standard treatments. The main goal was to check the drug's safety and find the best dose to use in future studies. Participants took EVT801 cap…
Phase: PHASE1 • Sponsor: Kazia Therapeutics Limited • Aim: Disease control
Last updated Jun 26, 2026 13:12 UTC
-
Can a 1950s antipsychotic help fight glioblastoma?
Disease control CompletedThis early-stage trial tested whether adding chlorpromazine, an old antipsychotic drug, to standard treatment (radiation and chemotherapy) is safe for people newly diagnosed with glioblastoma, an aggressive brain cancer. Ten adults took part. The main goal was to find a safe dose…
Phase: PHASE1 • Sponsor: Mohammed Milhem • Aim: Disease control
Last updated Jun 26, 2026 13:07 UTC
-
New scan could reveal hidden cancer cells
Diagnosis CompletedThis early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, m…
Phase: PHASE1 • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Diagnosis
Last updated Jun 27, 2026 14:03 UTC
-
Blow into this tube: a simple breath test might spot liver disease early
Diagnosis CompletedThis study looked at whether a breath test could help detect liver fibrosis, cirrhosis, or liver cancer. Researchers collected breath samples from 56 patients with known or suspected liver disease and analyzed them for specific chemical markers. The goal was to see if the test co…
Sponsor: Imperial College London • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
New PET tracer aims to light up hidden infections
Diagnosis CompletedThis early study tested a new radioactive tracer called 18F-FDS in 16 people with suspected bacterial or fungal infections. The tracer is designed to light up infection sites on PET/CT scans, helping doctors see exactly where an infection is. The goal was to check how the tracer …
Sponsor: Johns Hopkins University • Aim: Diagnosis
Last updated Jun 27, 2026 08:03 UTC
-
New radioactive tracer could sharpen cancer scans
Diagnosis CompletedThis early-phase trial tested a new radioactive imaging agent called 68Ga-NOTA-SNA002 in 17 adults with solid tumors. The agent was injected into a vein, and researchers checked its safety, how it spreads in the body, and how well it shows up on PET scans. The goal was to see if …
Phase: PHASE1 • Sponsor: SmartNuclide Biopharma • Aim: Diagnosis
Last updated Jun 26, 2026 18:18 UTC
-
New radioactive tracer tested for cancer imaging in tiny early trial
Diagnosis CompletedThis early-phase trial tested a single injection of a radioactive imaging agent called 68Ga-LNC1007 in 8 adults (healthy volunteers and solid tumor patients). The goal was to check its safety, how it moves through the body, and how well it shows up on scans. The study is already …
Phase: PHASE1 • Sponsor: Yantai LNC Biotechnology Singapore PTE. LTD. • Aim: Diagnosis
Last updated Jun 26, 2026 12:39 UTC
-
Can a pill shield ears from chemo damage?
Prevention CompletedThis study tests whether the drug SENS-401 can prevent hearing loss caused by cisplatin, a common chemotherapy. Adults with cancer who are scheduled to receive cisplatin take SENS-401 before, during, and after treatment. Hearing is measured with a standard test to see if the drug…
Phase: PHASE2 • Sponsor: Sensorion • Aim: Prevention
Last updated Jul 04, 2026 00:00 UTC
-
New catheter lock could slash infection risk for cancer patients
Prevention CompletedThis study tested whether a taurolidine-citrate solution (TauroLock) placed in the catheter between treatments can prevent bloodstream infections in adults with solid tumors receiving IV anti-cancer therapy. 162 patients were randomly assigned to get either the TauroLock solution…
Phase: NA • Sponsor: Centre Hospitalier Régional Metz-Thionville • Aim: Prevention
Last updated Jun 27, 2026 14:02 UTC
-
Text reminders help get young kids vaccinated on time
Prevention CompletedThis study tested whether sending text message reminders to parents could increase routine vaccination rates in children aged 0-2 years. Over 1,000 families in Brooklyn, New York, whose children were behind on vaccines received texts when shots were due or coming due. The goal wa…
Sponsor: NYU Langone Health • Aim: Prevention
Last updated Jun 27, 2026 12:33 UTC
-
New prosthetic grows with kids: no more frequent replacements?
Symptom relief CompletedThis study is testing a new type of prosthetic leg for children aged 3 to 18 that can be easily adjusted as they grow. The device is designed to be fitted in a single session and adjusted by the wearer. Researchers will measure comfort, socket pressure, walking speed, and quality…
Phase: NA • Sponsor: University of Pennsylvania • Aim: Symptom relief
Last updated Jul 04, 2026 00:00 UTC
-
Could tiny needles tame Chemo's Gut-Wrenching side effect in kids?
Symptom relief CompletedThis study tests whether acupuncture using tiny, semi-permanent needles can prevent diarrhea caused by the chemotherapy drug irinotecan in children with solid tumors. About 22 children will receive the acupuncture during their second round of chemo, and researchers will measure p…
Phase: NA • Sponsor: Fundació Sant Joan de Déu • Aim: Symptom relief
Last updated Jul 02, 2026 00:00 UTC
-
Cartoon calm: animated film may ease Kids' surgery fears
Symptom relief CompletedThis trial investigates whether a double-reading animated film, watched by both children and their parents before surgery, can reduce anxiety in children aged 3 to 7. The film uses avatars to walk the child through their hospital journey, from room to operating room. Researchers …
Phase: NA • Sponsor: University Hospital, Bordeaux • Aim: Symptom relief
Last updated Jun 27, 2026 14:02 UTC
-
Buzzy, coaching, or kaleidoscope: which best calms kids during cancer shots?
Symptom relief CompletedThis study tested three non-drug methods to reduce pain, fear, and anxiety during subcutaneous injections in 45 children aged 6–12 with cancer. The approaches were Buzzy® (a device that vibrates and cools the skin), a cognitive-behavioral coaching package, and a kaleidoscope for …
Phase: NA • Sponsor: Kocaeli University • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Paws for healing: therapy dogs may ease anxiety in kids with cancer
Symptom relief CompletedThis study looked at whether visits from specially trained therapy dogs could reduce distress and anxiety in children aged 5-17 who were hospitalized for cancer treatment. The researchers also checked if the visits increased germs on the children's hands, even with hand sanitizin…
Phase: NA • Sponsor: Kaiser Permanente • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
Simple skin care may shield kids from cancer drug side effects
Symptom relief CompletedThis study tested a preventive skin care routine in 14 children (ages 6 months to 18 years) with brain tumors who were receiving targeted therapy (BRAF, MEK, or Pan-RAF inhibitors). The goal was to see if gentle skin care and sun protection could reduce or prevent skin reactions …
Phase: PHASE2 • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drip combo aims to stop chemo nausea in kids
Symptom relief CompletedThis phase 3 trial tested whether giving a continuous, slow infusion of ondansetron (a common anti-nausea drug) plus dexamethasone (a steroid) could better control nausea and vomiting in children undergoing chemotherapy. The study enrolled 28 children aged 1 day to 18 years with …
Phase: PHASE3 • Sponsor: Immune Oncology Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
New drug may ease severe skin rashes in cancer patients
Symptom relief CompletedThis study tested whether the drug benralizumab can safely reduce skin rashes caused by cancer treatments like checkpoint inhibitors. The goal was to lower the number of high-grade rashes to milder ones, which could improve quality of life and help patients stay on their cancer t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Lower dose of olanzapine may ease chemo nausea with less drowsiness
Symptom relief CompletedThis study looked at 2,000 adults with solid tumors to find the best dose of olanzapine for preventing nausea and vomiting caused by strong chemotherapy. Researchers compared 2.5 mg, 5 mg, and 10 mg doses to see which works best with the fewest side effects like daytime sleepines…
Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 12:35 UTC
-
New pain coping program helps advanced cancer patients regain daily life
Symptom relief CompletedThis study tested a special pain coping skills program for people with advanced solid tumor cancer who have pain that interferes with daily activities. 211 patients were randomly assigned to either the program or standard care. The program taught ways to manage pain and find mean…
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Art therapy during chemo: mandala painting may ease fear and pain in young cancer patients
Symptom relief CompletedThis study tested whether a parent-child mandala painting activity during chemotherapy could reduce fear and pain in children with cancer and ease the burden on their caregivers. 108 children aged 5-12 and their parents took part, with half doing six 30-minute painting sessions o…
Phase: NA • Sponsor: Yuzuncu Yil University • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Diet and exercise boost health in kids battling cancer
Symptom relief CompletedThis study looked at whether giving diet advice and a simple exercise program could improve nutrition and reduce muscle loss in children aged 5-18 with cancer. 104 children took part, with half receiving the diet and exercise plan for three months while the other half waited. The…
Phase: NA • Sponsor: Jimma University • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Online play therapy boosts parenting confidence in pediatric cancer
Symptom relief CompletedThis study tested a 5-week online program that teaches parents of children with cancer how to use structured play to support their child's emotional needs. 60 parents took part, with half receiving the program and half not. The goal was to see if the program helps parents feel mo…
Phase: NA • Sponsor: serap güleç keskin • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Home workouts boost fitness in childhood cancer survivors
Symptom relief CompletedThis study tested a personalized exercise plan delivered at home via telehealth for childhood cancer survivors who have trouble exercising due to past treatment. 181 survivors took part to see if the program could improve their exercise capacity, heart and lung function, and qual…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:01 UTC
-
Video games help young cancer patients get moving and de-stress
Symptom relief CompletedThis study tested whether playing virtual reality games focused on exercise and mindfulness could help children with cancer be more active and feel better. Eleven kids participated in an 8-week program either right away or after a wait. Researchers measured steps per day and over…
Phase: PHASE1 • Sponsor: University of Alabama at Birmingham • Aim: Symptom relief
Last updated Jun 27, 2026 11:03 UTC
-
Can a single pill ease pain after liver cancer procedure?
Symptom relief CompletedThis study tested whether giving a single dose of pregabalin before a liver cancer ablation procedure can reduce pain afterward. 70 adults with liver cancer were randomly assigned to receive either pregabalin or a placebo before their procedure. The main goal was to measure pain …
Phase: PHASE4 • Sponsor: Sherief Abd-Elsalam • Aim: Symptom relief
Last updated Jun 27, 2026 11:01 UTC
-
Gentle gyrokinesis shows promise for easing fatigue in young cancer survivors
Symptom relief CompletedThis study looked at whether a gentle exercise program called Gyrokinesis could help reduce cancer-related fatigue in children and teens who had been treated for a brain tumor. 80 participants who had finished active treatment at least a year earlier took part. The study measured…
Phase: NA • Sponsor: MTI University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
Movie magic: new study tests films to keep kids still during cancer treatment
Symptom relief CompletedThis phase II trial tested an interactive movie system called PROMISE to help children aged 3-11 stay still during radiation therapy for cancer, aiming to reduce the need for general anesthesia. The study enrolled 30 children and compared the rate of anesthesia use to a historica…
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:09 UTC
-
New telehealth coaching aims to ease the financial burden of cancer
Symptom relief CompletedThis study tested a telehealth program called CC LinksTele that provides one-on-one coaching to help cancer survivors and their caregivers manage financial and legal issues related to cancer care. 124 adult patients and caregivers from a pediatric cancer clinic took part. The goa…
Phase: NA • Sponsor: Jean Edward • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Can walking and strength exercises help kids with advanced cancer?
Symptom relief CompletedThis study tested a personalized exercise program for children aged 5 to 17 with advanced cancer that cannot be cured. The program included walking on a treadmill and muscle-strengthening exercises, with the goal of seeing if it is safe and tolerable. Only 4 children took part, a…
Phase: NA • Sponsor: Assistance Publique Hopitaux De Marseille • Aim: Symptom relief
Last updated Jun 27, 2026 09:05 UTC
-
Personalized exercise program shows promise for reducing fatigue in children with cancer
Symptom relief CompletedThis study tested whether a personalized exercise program could help children and teens undergoing cancer treatment feel less tired and improve their quality of life. Nearly 500 participants did age-appropriate exercises like strength, balance, and endurance training for 30–60 mi…
Phase: NA • Sponsor: Johannes Gutenberg University Mainz • Aim: Symptom relief
Last updated Jun 27, 2026 09:03 UTC
-
Can virtual physio help kids with leukemia? small study tests hybrid approach
Symptom relief CompletedThis study tested whether a hybrid (in-person and online) physiotherapy program is feasible for children aged 4-17 with acute lymphoblastic leukemia. Ten children and their parents tried the program, which included tailored exercises and games. The goal was to see if families cou…
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 09:02 UTC
-
Can daily texts boost resilience in kids with cancer?
Symptom relief CompletedThis study tested a 12-week mobile phone program of daily reflection and meditation exercises for children with cancer and their families. The goal was to see if the program is practical and helpful for improving mental well-being and reducing anxiety and depression. Forty partic…
Phase: PHASE1 • Sponsor: Linkoeping University • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
App and brain zaps offer new hope for teen cancer survivors in pain
Symptom relief CompletedThis study looked at whether a mobile cognitive behavioral therapy (CBT) program, combined with a gentle brain stimulation technique called tDCS, could help teens who survived bone cancer manage chronic pain. Researchers first adapted the program for Black and Hispanic teens, the…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 09:01 UTC
-
Phone app may ease anxiety in teens and young adults after cancer
Symptom relief CompletedThis study tested a smartphone app designed to help young cancer survivors (ages 15-29) manage anxiety. The app uses attention bias modification (ABM) to retrain how the brain reacts to stressful triggers, along with gratitude exercises. The goal was to see if survivors would use…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Could a common cholesterol drug protect cancer Patients' hearing?
Symptom relief CompletedThis study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…
Phase: PHASE1, PHASE2 • Sponsor: Minia University • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Robotic baby seal boosts mood in hospitalized kids
Symptom relief CompletedThis study tested whether a robotic baby harp seal could help children aged 5-18 feel less anxious and more motivated during physical or occupational therapy in the hospital. Twenty-five kids used the robot during their sessions, and researchers measured their pain, anxiety, and …
Phase: NA • Sponsor: University of Nebraska • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Video game magic: AR adventure cuts opioid need in young cancer patients
Symptom relief CompletedThis study tested if playing an augmented reality game called SpellBound can help children with cancer feel less pain and need fewer opioids after surgery. 29 kids aged 5-15 who had never taken opioids before took part. The game was used alongside standard care to see if it impro…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 08:12 UTC
-
Shea butter and niacinamide cream may ease itching for immunotherapy patients
Symptom relief CompletedThis study tested whether using creams with niacinamide and shea butter can prevent or reduce skin itching in cancer patients receiving immunotherapy. 130 adults with solid tumors starting checkpoint inhibitor treatment were randomly assigned to use either the test cream or a con…
Phase: NA • Sponsor: Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau • Aim: Symptom relief
Last updated Jun 27, 2026 08:10 UTC
-
Can a palliative care team boost quality of life for cancer surgery patients?
Symptom relief CompletedThis study looked at whether having a palliative care team work alongside surgeons improves quality of life for patients with gastrointestinal cancers like pancreatic or liver cancer. About 379 patients and their family members took part. The main goal was to see if this team app…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Web-Based insomnia treatment shows promise for childhood cancer survivors
Symptom relief CompletedThis study tested an online insomnia treatment program for adult survivors of childhood cancer. Over 1,500 survivors participated, using a web-based program that teaches healthy sleep habits and cognitive behavioral techniques. The goal was to see if improving sleep could also bo…
Phase: NA • Sponsor: St. Jude Children's Research Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
No-Needle naptime: new trick helps toddlers through cancer treatment
Symptom relief CompletedThis study tested a simple, drug-free method called WASPE to help children aged 0-4 years stay still during radiation therapy for cancer. The method uses activities like watching videos, playing, and eating snacks to keep the child awake and calm. 48 children took part, and the g…
Phase: NA • Sponsor: Shandong Cancer Hospital and Institute • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
New app aims to ease symptoms for young cancer survivors
Symptom relief CompletedThis study tested a mobile app designed to help children aged 9 to 16 who recently finished cancer treatment manage their symptoms. The app also provides support for their caregivers. The goal was to see if the app is easy to use and helpful for symptom relief.
Phase: NA • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 08:06 UTC
-
New study tests better comfort care for liver patients
Symptom relief CompletedThis study tested two approaches to bring palliative care (comfort-focused care) to people with end-stage liver disease. About 1,500 adults from 19 U.S. centers took part. One group had direct access to a palliative care specialist; the other group saw a liver doctor specially tr…
Phase: NA • Sponsor: Albert Einstein Healthcare Network • Aim: Symptom relief
Last updated Jun 27, 2026 08:01 UTC
-
Can reiki ease cancer pain? small study says maybe
Symptom relief CompletedThis study tested whether Reiki, a relaxation therapy where a practitioner places hands on or near the body, could help cancer patients with symptoms like pain and fatigue. Ten adults with cancer who had at least three bothersome symptoms received up to six Reiki sessions. Resear…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 07:56 UTC
-
New program eases stress for latino parents of kids with cancer
Symptom relief CompletedThis study tested a culturally relevant program to help Spanish-speaking Latino caregivers of children with cancer feel less stressed and improve their quality of life. 33 caregivers took part, and the program focused on reducing anxiety and depression. The goal was to see if thi…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 07:54 UTC
-
New online program eases Kids' cancer return to school
Symptom relief CompletedThis study tested a web-based program to help children aged 8-17 with cancer adjust to returning to school. The program included modules for children, parents, teachers, and peers, focusing on communication, coping, and social skills. Twenty children participated, and researchers…
Phase: NA • Sponsor: Gazi University • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New tool helps kids with cancer speak up about symptoms
Symptom relief CompletedThis study tested whether having children with cancer report their symptoms three times a week using a web-based tool (SPARK) could improve their quality of life. The tool alerted healthcare providers and linked to care pathways for managing symptoms. A total of 445 children aged…
Phase: NA • Sponsor: The Hospital for Sick Children • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
New study tests monthly day care for advanced cancer patients
Symptom relief CompletedThis study looked at whether monthly visits to a hospital day care that includes palliative care can improve quality of life for adults with advanced cancer. 144 patients with a life expectancy between 2 and 12 months took part. Researchers measured changes in quality of life, fa…
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jun 26, 2026 18:50 UTC
-
Breathing workouts boost lung power in young kidney transplant recipients
Symptom relief CompletedThis study tested whether 8 weeks of respiratory muscle training using a special breathing device could improve lung function and muscle strength in 30 children aged 8-18 who had a kidney transplant at least 6 months earlier. The training involved both inspiratory and expiratory …
Phase: NA • Sponsor: Atlas University • Aim: Symptom relief
Last updated Jun 26, 2026 14:31 UTC
-
Child cancer study tracks brain and behavior over time
Knowledge-focused CompletedThis study looked at how cancer and its treatment affect thinking, memory, emotions, and behavior in children and teens. Researchers collected information from tests and surveys over time to understand these effects. The goal was to learn more, not to test a new treatment.
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Dust and crops: scientists hunt for Pesticide-Leukemia link in kids
Knowledge-focused CompletedThis study looked at 629 children in California to see if exposure to pesticides at home or from nearby farms is linked to childhood leukemia. Researchers collected dust from carpets and vacuum cleaners and mapped crops near homes. The goal was to measure chemical levels and see …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
New study tracks Radiation's toll on Kids' brains
Knowledge-focused CompletedThis study followed 76 children with brain tumors to learn how radiation therapy affects their quality of life, thinking, and body functions over time. Researchers collected blood, urine, and MRI scans before and after treatment, along with tests of memory, behavior, vision, and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Researchers review CAR T-Cell results in kids with B-ALL
Knowledge-focused CompletedThis study looked back at the medical records of 57 children and young adults (under 25) who received CAR T-cell therapy for B-cell acute lymphoblastic leukemia (B-ALL). The goal was to understand how well the treatment worked and what side effects occurred, especially in those w…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Can a Child's cancer be inherited? new study digs into family DNA
Knowledge-focused CompletedThis study looks at the DNA of 100 children (and young adults up to age 17) who have cancer, along with the DNA of their healthy parents. The goal is to find genetic changes that may have caused the cancer. By comparing the child's DNA to both parents', researchers hope to discov…
Phase: NA • Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
PET scan patients may soon be allowed to move freely during the long wait
Knowledge-focused CompletedThis study tested whether letting patients move freely between the injection of a radioactive tracer and the PET scan affects image quality. Normally, patients must rest for an hour to avoid muscle uptake that can blur results. The trial involved 284 adults with cancer or needing…
Phase: NA • Sponsor: Centre Hospitalier Régional d'Orléans • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Can a quick GP visit improve cancer care? new study aims to find out
Knowledge-focused CompletedThis study looks at whether it's possible for people diagnosed with solid tumors to have a follow-up visit with their general practitioner within 15 days of learning their diagnosis. Researchers will track how many patients actually attend this visit and why some might not. The g…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study examines artery complications in child liver transplants
Knowledge-focused CompletedThis study looked at 583 children who had liver transplants and later developed narrowing or blockage of the liver artery. Researchers wanted to find out how common these problems are and what treatments work best. The goal is to improve care and outcomes for future patients.
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Study aims to unlock secrets of immunotherapy skin reactions
Knowledge-focused CompletedThis study observed 255 cancer patients receiving immunotherapy to understand why some develop skin side effects. Researchers measured immune markers and lipids in the skin and blood. The goal is to identify patterns that could predict or explain these reactions.
Sponsor: National Jewish Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Kidney cancer patients in Real-World clinics get immunotherapy: does it work?
Knowledge-focused CompletedThis study followed 623 adults in France with advanced kidney cancer who were starting treatment with the immunotherapy drugs nivolumab (with or without ipilimumab) for the first time. Unlike a clinical trial, this was an observational study that simply tracked what happened in e…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Gene test spots hidden leukemia in kids
Knowledge-focused CompletedThis study looked at 148 children with T-cell acute lymphoblastic leukemia to see if a high-tech gene test could find tiny amounts of cancer left after treatment. Researchers used next-generation sequencing to check for specific gene changes in immune cells. They then compared th…
Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Study reveals why immunotherapy works differently in liver, lung, and brain tumors
Knowledge-focused CompletedThis study looked at medical records of 938 adults with solid tumors who received immunotherapy. Researchers compared how well the treatment worked when cancer had spread to different organs like the liver, brain, lung, or bone. The goal is to understand why some metastatic sites…
Sponsor: Wenlong Zhong, MD • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
Proton therapy gets a daily Tune-Up in small pilot study
Knowledge-focused CompletedThis pilot study tested whether it's possible to adjust proton radiation plans each day while the patient is on the treatment table. Ten adults with solid tumors took part. The goal was to see if this approach is safe and practical enough to study in a larger trial.
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:04 UTC
-
AI learns to spot cancer pain from faces and voices
Knowledge-focused CompletedThis study tested whether machine learning can detect cancer pain by analyzing facial expressions, voice, and speech. 83 people with cancer recorded videos at clinic visits and at home over 3 months. The goal was to see if this technology could classify pain levels in a diverse g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Massive cancer registry tracks genetic Testing's Real-World impact
Knowledge-focused CompletedThis completed registry followed nearly 8,000 adults with solid tumors who had next-generation sequencing (NGS) genetic testing. The goal was to collect real-world data linking test results, treatments, and survival. No new drug or intervention was tested; instead, the registry a…
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
8,000 kidney tumor samples collected to unlock cancer clues
Knowledge-focused CompletedThis completed research study collected and stored tumor tissue, blood, and urine samples from 8,000 children and young adults with kidney tumors. The goal was to help scientists study DNA changes and find biomarkers that could improve understanding of these cancers. No treatment…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Can genes predict late cancer treatment side effects?
Knowledge-focused CompletedThis study looked at nearly 4,000 childhood cancer survivors to see if their genes affect their risk of developing serious late complications like heart failure, stroke, bone damage, or a second cancer. Researchers compared survivors who had these problems with those who did not,…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New website aims to close cancer care gap for black patients
Knowledge-focused CompletedThis study created and tested an educational website to help Black and African American cancer patients learn about personalized cancer treatments and clinical trials. Researchers interviewed 48 patients and caregivers, then tested the website with 33 patients. The goal was to se…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
New breathing tube technique shows promise for kids in surgery
Knowledge-focused CompletedThis study looked at a different way to help children breathe during surgery. Instead of placing the breathing tube all the way into the windpipe, doctors placed it just above the vocal cords. The goal was to see if this method is easy, safe, and works well. The study included 85…
Sponsor: American University of Beirut Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
New training aims to help doctors catch child abuse earlier
Knowledge-focused CompletedThis study looked at whether a new educational program helps doctors-in-training better recognize and respond to child maltreatment. 84 medical residents from Canadian universities took part. The program was delivered either in a group with a leader or on their own. The goal was …
Phase: NA • Sponsor: McMaster University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:31 UTC
-
IPad brain games tested in young cancer survivors
Knowledge-focused CompletedThis study looked at whether children and teens who had a stem cell transplant for leukemia could use an iPad-based brain-training program. The main goal was to see if the program was practical and if kids would stick with it. Only 17 participants were enrolled, and the study foc…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Genetic testing could unlock new treatments for kids with brain cancer
Knowledge-focused CompletedThis study tested whether a detailed genetic analysis of tumor tissue could find treatment targets in 80 children with recurrent or very high-risk brain tumors. The goal was to see if this approach is practical and can help doctors choose personalized therapies. No new drugs were…
Phase: NA • Sponsor: Masaryk University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:28 UTC
-
Can the mediterranean diet survive chemo? new study investigates
Knowledge-focused CompletedThis study looked at how cancer treatment changes patients' ability to stick with a Mediterranean diet. Researchers followed 116 patients starting chemotherapy or immunotherapy, checking their diet adherence and sensory changes (taste and smell) at the start and after 9 weeks. Th…
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:26 UTC
-
New study reveals how COVID-19 affects kids with cancer
Knowledge-focused CompletedThis study looked at children and young adults under 24 who had COVID-19, including those with cancer. Researchers collected samples and medical information to learn about symptoms, risk factors, and how the virus spreads. The goal was to better understand the disease in younger …
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Tumor DNA test may match patients to smarter cancer drugs
Knowledge-focused CompletedThis study looked at whether analyzing the DNA of a patient's tumor can help doctors pick a targeted therapy for advanced or metastatic cancer. Researchers enrolled 550 adults with various solid tumors that had spread. They took biopsy or blood samples to search for genetic chang…
Phase: NA • Sponsor: Institut Paoli-Calmettes • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Can VR keep kids active and engaged after school? new study explores
Knowledge-focused CompletedThis study tested a virtual reality (VR) afterschool program for 32 children ages 9-17. The goal was to see if kids would use and enjoy the VR system, and to measure their physical activity. This was a pilot study to gather information, not to treat or cure any disease.
Phase: NA • Sponsor: University of Georgia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
New drug tracking study offers no cure, but key insights for future cancer treatments
Knowledge-focused CompletedThis study looked at how the drug tuvusertib is absorbed, broken down, and removed from the body in 12 people with advanced solid tumors. Participants received a tiny radioactive tracer to track the drug. The main goal was to understand the drug's path in the body, not to treat t…
Phase: PHASE1 • Sponsor: Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Immunotherapy side effects under the microscope: MOTIVATE study tracks 150 patients
Knowledge-focused CompletedThis study followed 150 people with solid tumors who were starting immunotherapy (immune checkpoint inhibitors) as part of their regular care. Researchers collected data on side effects and asked patients to fill out questionnaires before each treatment. The goal was to better un…
Phase: NA • Sponsor: Institut Claudius Regaud • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study aims to measure what matters most for kids with tough brain cancers
Knowledge-focused CompletedThis completed study looked at how re-irradiation affects the quality of life and symptoms of 20 children with diffuse intrinsic pontine glioma (DIPG) or recurrent brain tumors, as well as their caregivers. Researchers used surveys to track physical, emotional, and social well-be…
Sponsor: University of Calgary • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Hearing tests at local shops could help childhood cancer survivors catch hearing loss early
Knowledge-focused CompletedThis study tested a simple way for adult survivors of childhood cancer to get their hearing checked. Instead of going to a hospital, participants took a hearing test at a local hearing aid shop. The goal was to see if this approach could help more survivors find out if they have …
Phase: NA • Sponsor: University of Bern • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
Heart risk alert: troponin test may protect cancer patients on immunotherapy
Knowledge-focused CompletedThis completed study looked at 300 cancer patients treated with immune checkpoint inhibitors to see if measuring troponin levels could help detect serious heart problems early. The goal was to prevent major cardiovascular events like heart attack or stroke without unnecessarily s…
Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Cancer drug heart risk mystery probed in new study
Knowledge-focused CompletedThis study looked at how immune checkpoint inhibitors, a type of cancer drug, might affect blood vessels and increase heart risks. Researchers measured blood vessel function and checked for related markers in 39 cancer patients before and after starting treatment. The goal was to…
Phase: NA • Sponsor: Institut Mutualiste Montsouris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Tablets for tots: could eHealth revolutionize home care for sick children?
Knowledge-focused CompletedThis completed study tested whether giving families of children with long-term illnesses (like cancer, heart disease, or premature birth) a tablet computer with a special app helps them manage care at home. Researchers measured satisfaction, cost-effectiveness, and how well famil…
Phase: NA • Sponsor: Lund University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Manikin study tests best way to start CPR in kids
Knowledge-focused CompletedThis completed trial compared two ways to start CPR in a simulated child cardiac arrest: starting with chest compressions (AHA method) versus starting with rescue breaths (ERC method). Researchers used a manikin to measure how much air reached the lungs in the first minute. 28 he…
Phase: NA • Sponsor: Geneve TEAM Ambulances • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:03 UTC
-
Personalized medicine for kids with tough cancers: genetic profiling may point to better treatments
Knowledge-focused CompletedThis study looked at whether analyzing the DNA and RNA of children's relapsed or treatment-resistant tumors can help doctors pick targeted therapies. Researchers profiled tumors from 791 children and adolescents using advanced genetic sequencing. The goal was to see how many pati…
Phase: NA • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Breathing muscle training shows promise for childhood cancer survivors
Knowledge-focused CompletedThis study looked at whether a 6-week breathing muscle training program is possible for childhood cancer survivors and how it affects their breathing during exercise. Seven survivors who finished cancer treatment at least a year ago took part. The goal was to see if they could st…
Phase: NA • Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Pharmacist Check-Ups catch dangerous drug Mix-Ups in cancer care
Knowledge-focused CompletedThis study tested whether having a clinical pharmacist review medications for cancer patients before they start treatment could prevent drug-related problems. Researchers observed 440 adults with solid tumors who were about to receive chemotherapy, immunotherapy, or oral targeted…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Cancer drug side effect under the microscope: muscle enzyme spike studied
Knowledge-focused CompletedThis study looked at how often a muscle enzyme called CPK increases in people with solid tumors who are taking a type of targeted therapy called tyrosine kinase inhibitors (TKIs). Researchers measured CPK levels in routine blood tests from 154 patients and checked if high levels …
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Simple test may spot frailty in elderly cancer patients
Knowledge-focused CompletedThis study looked at how common frailty is in people aged 70 and older with solid tumors who visited a cancer center. Researchers used a short questionnaire called VES-13 to screen patients before their doctor visit. They also compared the test results with the doctor's own judgm…
Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Trial or standard care? study reveals emotional toll on cancer patients
Knowledge-focused CompletedThis study compared anxiety, depression, and quality of life between 125 cancer patients who joined clinical trials and those who received standard treatment. Researchers used questionnaires to measure stress and emotional well-being. The goal was to understand how trial particip…
Phase: NA • Sponsor: Centre Oscar Lambret • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Can adding radiation to immunotherapy help advanced cancer patients? new study explores safety and 'Abscopal' effects
Knowledge-focused CompletedThis study looked at 42 adults with advanced solid tumors who were already on or about to start checkpoint inhibitor immunotherapy and also needed palliative radiotherapy for symptom relief. Researchers wanted to see if the combination was safe (less than 30% severe side effects)…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
New study tackles bone pain caused by chemo-boosting drug
Knowledge-focused CompletedThis study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…
Sponsor: Ankara Etlik City Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Child cancer and birth defects: hidden genetic clues?
Knowledge-focused CompletedThis completed study collected information from nearly 1,000 children who had both cancer and developmental abnormalities like birth defects or growth issues. The goal was to find new genetic syndromes that make children more likely to develop cancer. Researchers analyzed blood a…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
Discarded tumor tissue yields clues for future brain cancer therapies
Knowledge-focused CompletedThis study looked at leftover tumor tissue and blood samples from 141 adults with glioblastoma or other solid tumors who were having surgery. The goal was to measure cell counts and viability to help scientists design better treatments for brain cancer and other solid tumors in t…
Sponsor: Thomas Jefferson University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Can a phone call help cancer survivors get the genetic answers they need?
Knowledge-focused CompletedThis study looked at whether offering genetic counseling by phone or video could help more childhood cancer survivors get genetic testing. About 391 survivors took part, comparing remote counseling to usual care. The goal was to see if remote services increase testing uptake and …
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Brain tumor Survivors' social lives under the microscope
Knowledge-focused CompletedThis study looked at how children who survived brain tumors interact with others. Researchers tested their thinking and social skills to see what helps or hurts their friendships. The goal was to learn more, not to test a new treatment.
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a simple survey predict survivor health? new study aims to find out
Knowledge-focused CompletedThis study looked at whether health questionnaires filled out by childhood cancer survivors and their parents match what doctors find during check-ups. About 300 survivors aged 8 to 18 took part, completing surveys over three years. The goal is to make these questionnaires more a…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Parents test new app to track baby eczema and gut health
Knowledge-focused CompletedThis completed study looked at how well parents of infants with early eczema and parents of healthy infants could use a mobile-friendly platform called OneBiome. The platform gives reports on the baby's gut microbiome and eating patterns. Researchers wanted to see if parents foun…
Sponsor: Danone Asia Pacific Holdings Pte, Ltd. • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New cancer drug interaction study: will antibiotics or antifungals change its effects?
Knowledge-focused CompletedThis study looks at how two common drugs—rifampicin (an antibiotic) and itraconazole (an antifungal)—affect the levels of a new cancer drug called BI 907828 in the blood. It involves 33 adults with advanced solid tumors who have not responded to previous treatments. Participants …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Childhood cancer survivors: pelvic Radiation's hidden toll on bladder and bones revealed
Knowledge-focused CompletedThis study looked at 32 childhood cancer survivors who had pelvic radiation at least one year earlier. Researchers measured bladder function and bone density to understand long-term side effects. The goal was to gather knowledge, not to test a new treatment.
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Leukemia Survivors' immunity under the microscope
Knowledge-focused CompletedThis study followed 89 children who finished chemotherapy for acute lymphoblastic leukemia (ALL) to see how their immune systems bounced back. Researchers measured antibody levels for vaccine-preventable diseases and tracked infections during the first year off treatment. The goa…
Sponsor: Children's Hospital of Philadelphia • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:14 UTC
-
AI model predicts brain fog risk in kids after tumor surgery
Knowledge-focused CompletedThis study looked at medical records of 600 children who had brain tumor surgery to find out which kids might have long-term thinking or memory problems. Researchers used machine learning to create a tool that predicts this risk based on brain scans, tumor details, and treatment …
Sponsor: West China Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Can yoga and massage help kids with cancer? new study tests data collection
Knowledge-focused CompletedThis study looked at how to gather information about complementary therapies (like massage, yoga, or acupuncture) for children with cancer. Researchers worked with 100 kids to see if it's possible to measure things like pain, nausea, and quality of life during these treatments. T…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Cancer patients happier getting immunotherapy at home?
Knowledge-focused CompletedThis French study asked 49 cancer patients how they felt about switching from hospital to home-based immunotherapy. The goal was to see if home treatment improved their satisfaction with care. It was an observational study, meaning no new treatments were tested—just patient exper…
Sponsor: Bristol-Myers Squibb • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Scientists try out new tools to feel how hard tumors are
Knowledge-focused CompletedThis study tested two new methods to measure pressure and stiffness inside solid tumors in 27 patients. One method uses a thin catheter to measure pressure directly, and the other uses sound waves like an ultrasound to check stiffness. The goal was to see if these measurements co…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
Formula showdown: which one helps sick Kids' gut bugs?
Knowledge-focused CompletedThis study compared two types of liquid food (Pediasure and Nourish) to see how they affect the gut bacteria in 32 critically ill children ages 1-17 in the ICU. Researchers collected stool and saliva samples to track changes in the microbiome. The goal was to understand how diffe…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:10 UTC
-
New scan may spot hidden heart harm in childhood cancer survivors
Knowledge-focused CompletedThis completed study looked at 80 childhood cancer survivors who had received high doses of anthracycline chemotherapy. Researchers used cardiac MRI and blood tests to find early signs of heart damage that standard tests might miss. The goal was to see if these advanced methods c…
Sponsor: Connecticut Children's Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Childhood leukemia chemo leaves lasting nerve damage in survivors
Knowledge-focused CompletedThis study looked at how common nerve damage is in adults who had vincristine chemotherapy for childhood leukemia. 467 survivors were assessed using a questionnaire about nerve symptoms. The goal was to understand how often and how severe this side effect is long after treatment …
Sponsor: University Hospital, Clermont-Ferrand • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC
-
Can a machine read pain in silent kids?
Knowledge-focused CompletedThis study tested whether a device called the ANI monitor can measure pain in sedated children aged 2 and older in the pediatric intensive care unit. Researchers watched how the device responded during painful care and compared it to a standard behavioral pain scale. The goal was…
Sponsor: University Hospital, Lille • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:05 UTC
-
Chatbot 'Penny' aims to reconnect cancer survivors with life-saving follow-up care
Knowledge-focused CompletedThis study tested a chatbot named Penny that sends text messages to help adult survivors of childhood or young adult cancers schedule follow-up appointments, lab work, and scans. The goal was to see if survivors who had not been to a clinic in over three years would use the chatb…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Chemo nausea still a problem despite standard care, study finds
Knowledge-focused CompletedThis study tracked 300 cancer patients receiving their first round of chemotherapy to see how often nausea and vomiting still happen, even with standard anti-nausea medicines. Participants filled out questionnaires about their symptoms in the first 24 hours and up to 4 days after…
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:04 UTC
-
Your iPhone could be your next cancer symptom tracker
Knowledge-focused CompletedThis study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Question list boosts cancer Patients' confidence and reduces anxiety
Knowledge-focused CompletedThis study tested whether giving cancer patients a list of questions to ask their doctors helps them feel more empowered and less anxious. About 96 patients, along with nurses and doctors, took surveys and shared their experiences. The goal is to improve communication and make pa…
Phase: NA • Sponsor: Marmara University • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Smart devices track cancer recovery at home
Knowledge-focused CompletedThis study tested whether using at-home monitoring devices (like a wristband pedometer, scale, and blood pressure cuff) can help improve care for cancer patients after they leave the hospital following surgery. 22 patients with various cancers participated. The goal was to see if…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:02 UTC
-
Immunotherapy side effects under the microscope: new study monitors autoantibodies
Knowledge-focused CompletedThis completed study followed 183 cancer patients starting checkpoint inhibitor therapy to see how often they develop autoantibodies—proteins that can mistakenly attack the body's own tissues. Researchers collected blood samples to track changes in several types of autoantibodies…
Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
App vs. paper: which diary boosts cancer pill adherence?
Knowledge-focused CompletedThis study tested whether an electronic diary app helps cancer patients take their oral medications more consistently than a traditional paper diary. A total of 124 adults with solid tumors or blood cancers were randomly assigned to use either the app or a paper diary to track th…
Phase: NA • Sponsor: Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New registry tracks young brain tumor patients to boost research
Knowledge-focused CompletedThis registry collected information and biological samples from 354 children and young adults diagnosed with certain brain tumors like medulloblastoma and ependymoma. The goal was to improve diagnostic standards through expert review and to gather data for future research. No new…
Sponsor: Universitätsklinikum Hamburg-Eppendorf • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Can a simple spit test predict chemo-related deafness in kids?
Knowledge-focused CompletedThis study looked at 119 children who had platinum-based chemotherapy for certain cancers. Researchers wanted to find out if certain genes make some kids more likely to develop hearing loss from the treatment. By analyzing DNA from saliva samples, they hope to identify high-risk …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Hidden diabetes risk in hepatitis c kids?
Knowledge-focused CompletedThis observational study checked whether children with hepatitis C who also have thalassemia or survived childhood cancer are more likely to develop insulin resistance (a step toward diabetes). Researchers compared 90 infected children to healthy kids of the same age and gender. …
Sponsor: Ain Shams University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Cancer patients with COVID: do early antiviral drugs help?
Knowledge-focused CompletedThis completed study looked at how well early COVID-19 antiviral therapies work in cancer patients. Researchers tracked 112 patients with solid tumors who received these treatments to see how many needed hospitalization within 14 days. The goal is to fill knowledge gaps and impro…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC
-
Gene-Based dosing study aims to make cancer drug safer
Knowledge-focused CompletedThis early-phase study tested the safety and drug levels of belinostat in 17 patients with advanced solid tumors or blood cancers that had not responded to prior treatments. Researchers grouped patients by their UGT1A1 gene type to see if genetic differences affect how the drug i…
Phase: PHASE1 • Sponsor: Acrotech Biopharma Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Should all young cancer patients get genetic testing? study investigates
Knowledge-focused CompletedThis study looked at whether offering genetic testing to all young adults with cancer (ages 18-39) is better than only testing those who meet certain guidelines. About 749 participants were randomly assigned to either universal testing with a broad gene panel or standard testing …
Phase: NA • Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:54 UTC
-
New telemedicine service brings nighttime care to children in ghana
Knowledge-focused CompletedThis study tested a new service that lets parents call for medical help at night and get medicine delivered to their home for their sick children. Over 1,200 children with common illnesses like pneumonia, diarrhea, or malaria took part in three communities in Ghana. The goal was …
Phase: NA • Sponsor: University of Florida • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:52 UTC
-
New tool aims to ease tough talks on cancer drug resistance
Knowledge-focused CompletedThis study aimed to create a communication tool to help doctors and patients discuss when cancer stops responding to treatment. Researchers interviewed 128 people, including patients with certain breast cancers, metastatic uveal melanoma, parents of children with cancer, and heal…
Phase: NA • Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 19:09 UTC
-
Drug interaction study tests liver enzyme effects on cancer treatment
Knowledge-focused CompletedThis study looked at how bosentan, a drug that affects liver enzymes, changes the levels of the cancer drug lurbinectedin in the blood. Eleven adults with advanced solid tumors received lurbinectedin alone and with bosentan. The goal was to see if bosentan alters how the body pro…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 18:46 UTC
-
New registry aims to sharpen use of precision radiation for cancer
Knowledge-focused CompletedThis study created a registry of 149 cancer patients who received a precise type of radiation called SBRT. The goal was to track how doctors use this treatment in four different situations: for cancer that has spread to a few spots, after chemotherapy, before starting chemotherap…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:50 UTC
-
Which bone-rebuilding method works best for kids with leg tumors?
Knowledge-focused CompletedThis study looked back at medical records of 91 children who had a malignant bone tumor removed from their leg and then had the bone rebuilt using one of three techniques: induced membrane, vascularized fibula, or vascularized fibula plus a bone graft. The goal was to compare how…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:02 UTC
-
Brain scans reveal hidden memory damage in childhood cancer survivors
Knowledge-focused CompletedThis study looked at how radiation therapy for pediatric brain cancer affects memory and brain structure in children, teens, and young adults. Researchers used MRI scans and memory tests to compare 60 participants. The goal is to better understand which brain areas are harmed by …
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Jun 26, 2026 14:09 UTC
-
New PET/MRI scan could help kids with brain tumors get better treatment
Knowledge-focused CompletedThis study tested whether a special type of brain scan (PET/MRI) can be used in children aged 5-17 with brain tumors. The scan combines two imaging techniques to give doctors more information about the tumor. Only 15 children took part, and the main goal was to see if the scan wa…
Phase: NA • Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:40 UTC
-
Small study tests drug interaction in advanced cancer patients
Knowledge-focused CompletedThis Phase 1 study looked at how the antifungal drug itraconazole affects the levels of the cancer drug lurbinectedin in 14 patients with advanced solid tumors. The goal was to understand potential drug interactions, not to treat the cancer. Results may guide future dosing and sa…
Phase: PHASE1 • Sponsor: PharmaMar • Aim: Knowledge-focused
Last updated Jun 26, 2026 12:50 UTC